Welcome to our dedicated page for Concord Medical news (Ticker: CCM), a resource for investors and traders seeking the latest updates and insights on Concord Medical stock.
Concord Medical Services Holdings Limited reports developments as a China-based oncology healthcare provider focused on cancer diagnosis, treatment, research, education and prevention. Its updates center on self-owned cancer hospitals and clinics, partnered hospitals, and oncology service lines that include radiotherapy, diagnostic imaging, hospital operations and premium cancer care.
Recurring news covers financial results for the hospital and network businesses, annual reports on Form 20-F, shareholder meetings, and governance actions. Company and subsidiary announcements also address Concord Healthcare Group, its Hong Kong-listed H shares, proton therapy operations at Guangzhou Concord Cancer Hospital, medical-device approvals tied to proton equipment, treatment milestones, and oncology technology such as a proton therapy large language model.
Concord Medical Services Holdings Limited (NYSE: CCM) reported its unaudited consolidated financial results for the first half of 2020, revealing total net revenues of RMB83.0 million ($11.7 million), a 16.6% decline from the previous year. The company suffered a gross loss of RMB3.5 million ($0.5 million) compared to a gross profit of RMB3.1 million in the same period last year. Net loss attributable to shareholders was RMB128.8 million ($18.2 million), showing a slight improvement from RMB140.1 million in 2019. The newly opened Imaging Diagnosis Center is expected to enhance future revenue growth.